Less than one in 10 individuals that would benefit from obesity jabs such as Wegovy are able to get them, caution the WHO as it issues its first recommendations on the therapies.
Given in excess of 1,000,000,000 people worldwide currently classified as obese, it is advocating for broader and more equitable access to these injectable treatments.
Per projections, more than two billion will be obese by 2030 without intervention.
"The latest guidelines acknowledges that obesity is a lifelong illness that can be treated with holistic and lifelong treatment," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and distribution challenges are major obstacles to universal access to the jabs that can assist patients in reducing substantial body mass, notes the organization.
Skinny Jab Shortage
Despite the current most favorable case, the supply of such drugs might only reach about 100 million people – under 10% of the global need, per the WHO.
The advice encourages countries and companies to expand availability, via strategies such as patent sharing.
Exclusive production rights on semaglutide – the core component of a leading brand – is due to expire in multiple nations in 2026.
The Way Weight-Loss Drugs Work
The injections replicate a body's own hormone to delay gastric emptying, curb appetite and enhance satiety so users reduce food intake.
Individuals commonly see weight reduction within a few weeks of commencing the weekly injections.
Studies indicates patients may regain a significant portion after a year of stopping the drug, as their normal food cravings resume.
Being overweight or obese elevates your chance for developing diseases, including type 2 diabetes, heart disease, stroke, and certain malignancies.
Excess weight affects individuals in all nations and was linked to 3.7 million deaths worldwide in 2024, according to the health agency.
